Stiefel seeks FDA approval for tazarotene foam

RESEARCH TRIANGLE PARK, N.C. — GlaxoSmithKline company Stiefel announced it is seeking approval for a facial acne treatment in patients ages 12 years and older.

Stiefel said it has submitted a new drug application to the Food and Drug Administration for tazarotene foam. Tazarotene foam is subject to evaluation and approval by the regulatory authorities before it can be made available to physicians for prescribing to their appropriate patients, Stiefel said.

Last month, Stiefel brought to market its Revaleskin-branded anti-aging treatment, Revaleskin Illuminesse Brightening Complex.